Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

Sponsor
Peking Union Medical College Hospital
Study ID
NCT04583020
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
  • radiation — RADIATION
    60Gy/30
  • Temozolomide — DRUG
    Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles

Study Details

The purpose of this research is to study the safety and efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas.

Key Dates

Start date
Nov 12, 2020
Status verified
Nov 2020
Primary completion
Dec 30, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant PD-1 inhibitor
    Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.

Primary Outcome Measure

Overall survival (OS) [ Time Frame: up to 12 months ]

Central Contacts

Related Studies